Radiation Therapy With or Without RSR13 in Treating Patients With Brain Metastases

Completed · Phase 3

Conditions studied: Metastatic Cancer

In brief

RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs such as RSR13 may make tumor cells more sensitive to radiation therapy. PURPOSE: Randomized phase III trial to compare the effectiveness of radiation therapy to the brain with or without RSR13 in treating patients who have brain metastases.

Key facts

Study ID
NCT00005887
Run by
Spectrum Pharmaceuticals, Inc
Starts
2000-02-01
Expected to finish
2003-01-01
Last updated by the study team
2021-08-23

Who can join

Age: 18 and older, up to 120. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.